Efficacy and Safety of Caspofungin in Children with Invasive Fungal Infections | CMAC

Efficacy and Safety of Caspofungin in Children with Invasive Fungal Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):193-200

​ Klimko N.N., Kolbin A.S., Tchugunov A.O., Maschan M.A., Skorobogatova E.V., Tchupova N.V., Afanasiev B.V., Teletaeva G.M., Kumirova E.V., Taranushenko T.E., Mentkevich G.L.
invasive fungal infections children caspofungin treatment direct costs
Section
Personal Experience
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):193-200

Abstract

The prospective study of 19 children (aged of 1 to 17 years) with invasive fungal infections and different forms of immunosupression was conducted. Clinical and microbiological efficacy and safety of caspofungin, as well as analysis of direct costs of treatment of invasive fungal infections were performed. Caspofungin is found to be efficacious and safe antifungal agent both for empirical and directed therapy of invasive candidiasis and aspergillosis in all age groups children. Analysis of direct costs showed that cost of caspofugin is a main component of direct costs in the treatment of invasive fungal infections (86 to 93%).

  • 1. Groll A.H., Walsh T.J. Fungal infections in the pediatric patient. In: Anaissie E.J., McGinnis M.R., Pfaller M.A., editors. Clinical mycology. 1 st ed. New York: Churchill Livingstone; 2003. p. 417-42.
  • 2. Walsh T.J., Gonzalez С., Lyman С.А., et al. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996; 11:187-290.
  • 3. Климко Н.Н., Колбин А.С. Перспективы использования новых системных противогрибковых препаратов в педиатрии (обзор литературы). Проблемы медицинской микологии 2005; 7(3):3-11.
  • 4. Deresinski S.C., Stevens D.A. Caspofungin. Clin Infect Dis 2003; 36:1445-57.
  • 5. Committee on Infectious Diseeses American Academy of Pediatrics. Red Book: 2003 Report. Elk Grove Village, IL: American Academy of Pediatrics; 2003.
  • 6. Ascioglu S., Rex J.H., Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: an internation consensus. Clin Infect Dis 2002; 34:7-14.
  • 7. EORTC Internation Antimicrobaial Therapy Cooperative Group. Empiric antifungal therpy in febrile granulocytopenic patients. Am J Med 1989; 86:669-72.
  • 8. Клясова Г.А. Практические рекомендации по антибактериальной терапии инфекций у пациентов с нейтропенией. Клин микробиол антимикроб химиотер 2003; 5:47-73.
  • 9. Клинико-экономический анализ (оценка, выбор медицинских технологий и управление качеством медиццинской помощи). М.А. Авксентьев, В.Б. Герасимов, М.В.Сура. Под ред. П.А. Воробьева. М.:Ньюдиамед; 2004. 404 с.
  • 10. Мохов О.И., Белоусов Д.Ю. Методология планирования клинических исследований. Качественная клиническая практика 2001; 1:8-20.
  • 11. Энциклопедия лекарств. 12-й вып. Гл.ред. Г.Л.Вышковский. М.:РЛС-2005,2004. 1440 с. (Серия «РЕГИСТР ЛЕКАРСТВЕННЫХ СРЕДСТВ РОССИИ»).
  • 12. Гублер Е.В. Вычислительные методы анализа и распознавания патологических процессов. Л.: Медицина; 1978. 296 с.
  • 13. Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины: Пер. с англ. – М.: Медиа Сфера; 1998. 347 с.
  • 14. Gardner M.J., Altman D.G. Statisitics with confidence. Brit Med J publications. Reprint. 1994. p. 51-52.
  • 15. Altman D.G. Confidence intervals for the number needed to treat. Brit Med J 1998; 317:1309-12.
  • 16. Bland M., Altman DG. Statistics Notes: The odds ratio. Brit Med J 2000; 320:1468.
  • 17. Groll A.H., Walsh T.J. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10:1545-58.
  • 18. Stone J.A., Holland S.D., Wickersham P.J., et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739-45.
  • 19. Neely M., Blumer J. Pharmacokinetic characteristics of caspofungin in two pediatric liver transplantant patients. Curr Ther Res Clin Exp 2003; 64:127-136.
  • 20. Gilbert D.N., Moellering R.C., Epiopoulos G.M., Sande M.A., editors. The Sanford guide to antimicrobial therapy 35th ed. USA; 2005.
  • 21. Franklin J.A., McCormick J., Flynn P.M. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003; 22:747-9.
  • 22. Voitl P., Scheibenpflug C., Weber T., et al. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 2002; 21:632-4.
  • 23. Sallmann S., Heilmann A., Heinke F., et al. Capofungin therapy for Aspergillus lung infection in a boy with chronic granulomatous disease. Pediatr Infect Dis J 2003; 22:199-200.
  • 24. Mrowczynski W., Wojtalik M. Caspofungin for Candida endocarditis. Pediatr Infect Dis J 2004; 23:376.
  • 25. Wertz K.K., Pretzlaff R.K. Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med 2004; 5:181-3.
  • 26. Hesseling M., Weindling M., Neal T. First reported use of caspofungin in an extremely low-birth-weight neonate. J Matern Fetal Neonatal Med 2003; 14:212.
  • 27. Eccles M., Freemantle N., Mason J. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. Brit Med J 1998; 316:1232-35.
  • 28. Antachopoulos C., Walsh T.J. New agents for invasive mycoses in children. Curr Opin Pediatr 2005; 17:78-87.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared